Kalvista Pharmaceuticals Inc (KALV) Stock Price, Quote & News

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formu...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 999 0075

Fax: 866 553 3269

Website: www.kalvista.com

Address:

55 Cambridge Parkway, Suite 901 East, Cambridge, United States

ALOSETE Oct. 24 at 4:12 PM

$KALV Very cheap. Could run any day now.

0 · Reply

debilian Oct. 21 at 3:20 PM

$KALV Yo Ho Ho! and a bottle of rum!

0 · Reply

CrispDry Oct. 15 at 8:34 PM

$KALV what’s this after hours action? I show up 44 cents 800k traded

0 · Reply

BiotechBonesaw Oct. 13 at 3:36 PM

$ALT $CCCC $IMRX $KALV $TNXP buy the dip of any of these five oversold biotech beauties and hold long 🚀

0 · Reply

GrandmaMoneybaggs Oct. 8 at 4:29 PM

$KALV

0 · Reply

Shakattack31 Oct. 8 at 4:24 PM

$KALV glad i didn't sell yesterday

0 · Reply

BiotechBonesaw Oct. 7 at 4:25 PM

$CRMD $GERN $IBRX $KALV $SLNO this is a great point. Holding Kalvista but even as a novel oral approval in a rare disease, this company is not getting the respect that an oncology launch would

0 · Reply

Night_Owl_Biotech Oct. 7 at 1:44 AM

To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO

0 · Reply

BlakeCanyon50 Oct. 6 at 9:27 PM

$KALV I took a fairly large position today. Can’t believe they dropped this in $10’s.

0 · Reply

TwongStocks Oct. 6 at 8:01 PM

$KALV KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe https://www.businesswire.com/news/home/20251006039455/en/KalVista-Pharmaceuticals-Presents-New-Data-Highlighting-the-Potential-of-EKTERLY-sebetralstat-to-Transform-On-Demand-Hereditary-Angioedema-Treatment-in-Europe "With EKTERLY now approved in the European Union, we look forward to bringing this innovation to more people living with HAE—beginning with a launch in Germany this quarter followed by additional European launches in 2026 and beyond.”"

0 · Reply

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

Oct 6, 2025, 7:00 AM EDT - 19 days ago

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

Oct 3, 2025, 7:00 AM EDT - 22 days ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2025, 7:00 AM EDT - 23 days ago

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

Sep 26, 2025, 7:00 AM EDT - 4 weeks ago

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

Sep 24, 2025, 10:52 PM EDT - 4 weeks ago

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

Sep 24, 2025, 4:01 PM EDT - 4 weeks ago

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

Sep 19, 2025, 7:00 AM EDT - 5 weeks ago

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

Sep 11, 2025, 11:43 AM EDT - 6 weeks ago

KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript

Sep 11, 2025, 7:00 AM EDT - 6 weeks ago

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

Sep 10, 2025, 7:06 AM EDT - 6 weeks ago

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sep 7, 2025, 10:12 PM EDT - 6 weeks ago

KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 7:05 AM EDT - 7 weeks ago

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

Aug 27, 2025, 7:00 AM EDT - 2 months ago

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

Aug 11, 2025, 4:05 PM EDT - 2 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

MGX

Aug 11, 2025, 7:00 AM EDT - 2 months ago

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

Jul 25, 2025, 8:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

Jul 15, 2025, 4:05 PM EDT - 3 months ago

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

Jul 10, 2025, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

Jul 8, 2025, 3:52 PM EDT - 3 months ago

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

Jul 7, 2025, 6:37 AM EDT - 3 months ago

US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:30 AM EDT - 3 months ago

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

Jun 26, 2025, 7:00 AM EDT - 4 months ago

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

Jun 16, 2025, 7:00 AM EDT - 4 months ago

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

Jun 13, 2025, 4:41 PM EDT - 4 months ago

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

Jun 13, 2025, 4:05 PM EDT - 4 months ago

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

Jun 5, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

Jun 2, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

May 29, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

Apr 30, 2025, 7:00 AM EDT - 6 months ago

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Apr 12, 2025, 12:42 AM EDT - 7 months ago

KalVista: Poised For Rare Disease Transformation

Apr 8, 2025, 6:30 AM EDT - 7 months ago

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

Mar 31, 2025, 7:00 AM EDT - 7 months ago

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 7:00 AM EDT - 7 months ago

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Mar 12, 2025, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Mar 10, 2025, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Mar 3, 2025, 7:00 AM EST - 8 months ago

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 24, 2025, 7:00 AM EST - 8 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Feb 21, 2025, 7:00 AM EST - 8 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 10, 2025, 7:00 AM EST - 9 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Jan 21, 2025, 7:00 AM EST - 9 months ago

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Dec 18, 2024, 1:46 PM EST - 11 months ago

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025

Dec 16, 2024, 7:00 AM EST - 11 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 5, 2024, 6:30 AM EST - 11 months ago

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Nov 26, 2024, 7:00 AM EST - 11 months ago

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

Nov 4, 2024, 7:05 AM EST - 1 year ago

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

Nov 4, 2024, 7:00 AM EST - 1 year ago

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

Oct 28, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

Oct 18, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

ALOSETE Oct. 24 at 4:12 PM

$KALV Very cheap. Could run any day now.

0 · Reply

debilian Oct. 21 at 3:20 PM

$KALV Yo Ho Ho! and a bottle of rum!

0 · Reply

CrispDry Oct. 15 at 8:34 PM

$KALV what’s this after hours action? I show up 44 cents 800k traded

0 · Reply

BiotechBonesaw Oct. 13 at 3:36 PM

$ALT $CCCC $IMRX $KALV $TNXP buy the dip of any of these five oversold biotech beauties and hold long 🚀

0 · Reply

GrandmaMoneybaggs Oct. 8 at 4:29 PM

$KALV

0 · Reply

Shakattack31 Oct. 8 at 4:24 PM

$KALV glad i didn't sell yesterday

0 · Reply

BiotechBonesaw Oct. 7 at 4:25 PM

$CRMD $GERN $IBRX $KALV $SLNO this is a great point. Holding Kalvista but even as a novel oral approval in a rare disease, this company is not getting the respect that an oncology launch would

0 · Reply

Night_Owl_Biotech Oct. 7 at 1:44 AM

0 · Reply

BlakeCanyon50 Oct. 6 at 9:27 PM

$KALV I took a fairly large position today. Can’t believe they dropped this in $10’s.

0 · Reply

TwongStocks Oct. 6 at 8:01 PM

0 · Reply

CH_Expat Oct. 6 at 5:12 PM

$KALV Starter in single digits, would prefer 8s.

0 · Reply

edelhead Oct. 6 at 2:26 PM

$KALV It's bizarro world again - Kalvista adds two talented people to the leadership team today and the stock goes down. What a disconnect! This stock will go up like crazy any time now, and I am and will be a Kalvista shareholder for that!!

3 · Reply

BioGem Oct. 5 at 5:14 AM

$KALV I added more to my short since they took on debt. It means 2 negative things: 1-Cash is rapidly dwindling due to costly sales and marketing team and they are desperate, 2-Interest costs on this debt will be added to an already disastrous bottom line. Q3 numbers will be ugly.

0 · Reply

edelhead Oct. 2 at 4:21 PM

$KALV the company adds a director, and announces approval of all proposals at the annual meeting - sounds very positive to me. The stock is tanking anyway - we live in bizarro world!

1 · Reply

TwongStocks Oct. 2 at 11:33 AM

$KALV Bethany L. Sensenig, CFO at Radius Health, appointed to the Board of Directors. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-appointment-bethany-l

0 · Reply

BiotechBonesaw Oct. 1 at 11:49 AM

$FBIO it has happened before. $KALV was delayed for weeks a few months ago due to RFKJ’s cuts to the FDA. This shutdown and banana republic leadership in Washington isn’t helping manners. Hopefully we find out soon 🕰️

0 · Reply

buckdatrend13 Sep. 29 at 9:51 PM

$KALV Ten analysts have an average one-year price target of $32!!!!

1 · Reply

MakeMoneyAZ Sep. 26 at 4:40 PM

$KALV Bought more. Whats the consensus on this? When we mooning?

0 · Reply

edelhead Sep. 25 at 6:53 PM

$KALV This stock price reaction today is unbelievably ridiculous. You would think from the drop that there is immediate dilution coming at $12. BUT THAT IS NOT WHAT IS HAPPENING IN REALITY. I am frustrated for one reason - because I don't enough cash to buy more shares at this artificially and insanely depressed price!!

0 · Reply

edelhead Sep. 25 at 4:05 PM

$KALV The market reaction today should be the opposite from what is happening. It seems like the potential future dilution is approx. 15%, but only if the stock price first goes up approx. 40%. And in the meantime the company can use the $125 mill to support its worldwide growth. Maybe I'm missing something, but I'm liking this convertible bond deal.

1 · Reply

CH_Expat Sep. 25 at 3:53 PM

$KALV Almost there.

0 · Reply

redrussian Sep. 25 at 1:54 PM

$KALV $ACU stopped out kalv sold acu 42.00

0 · Reply

Market Cap	555.75M
Revenue (ttm)	0.00
Net Income (ttm)	-183.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,223,600
Avg Vol	1,178,344
Day's Range	N/A - N/A
Shares Out	50.52M
Stochastic %K	26%
Beta	-0.15
Analysts	Strong Sell
Price Target	$30.67